Terminated PHASE2 INTERVENTIONAL 1-arm NCT00969332

A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease (FO)

Omegaven and Parenteral Nutrition Associated Cholestasis

Sponsor: University of California, Los Angeles

Interventions Omegaven

Updated 8 times since 2017 Last updated: Feb 11, 2020 Started: Aug 31, 2009 Primary completion: Jan 12, 2019 Completion: Feb 12, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

study intervention was approved by the FDA

Other terminated trials from University of California, Los Angeles

See all terminations from University of California, Los Angeles

Listed as NCT00969332, this PHASE2 trial focuses on Cholestasis and remains terminated or withdrawn. Sponsored by University of California, Los Angeles, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Mar 2020 — Jan 2021 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated

▶ Show 3 earlier versions

Jun 2018 — Mar 2020 [monthly]

Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of California, Los Angeles

Data source: University of California, Los Angeles

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States